Compare GSK plc (GSK) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Procter & Gamble Co — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Procter & Gamble Co trades at $151.23 (market cap $349.77B). The key difference: Procter & Gamble Co is far larger — about 3.8× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Procter & Gamble Co for 131 Days on average.
| GSK | PG | |
|---|---|---|
Market Cap | $91.88B | $349.77B |
Volume | 7,730,529 | 10,055,825 |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $167.18 |
52-Week Low | $43.24 | $138.10 |
Typical Hold Time | 93 Days | 131 Days |
Enterprise Value | $111.88B | $375.61B |
Dividend Yield | 3.9% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Procter & Gamble (PG) trades at $150.59, up 1.87% with bullish technical momentum as it approaches resistance near $151. The company demonstrates strong fundamentals with consistent earnings beats, 18.44% net margins, and robust cash flow generation. Recent partnership with the WNBA highlights strategic brand expansion while maintaining a 69-year dividend growth streak. Valuation metrics show premium multiples relative to peers, with P/E at 22.75 and P/S at 4.19.
PG offers stable growth with dividend reliability but faces valuation concerns amid modest revenue expansion. The consensus price target of $160.13 suggests 6.3% upside potential, supported by 53 analyst ratings favoring Buy (52.8%). Key risks include premium valuation pressure and competitive market dynamics. The stock presents a defensive investment opportunity with consistent cash flow generation in consumer staples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
